Medindia

X

Abaxis to Report First Quarter Fiscal 2011 Financial Results Thursday, July 29, 2010

Monday, July 19, 2010 General News J E 4
Advertisement


UNION CITY, Calif., July 19 Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the first quarter of fiscal year 2011, ended June 30, 2010. The call will be at 4:15 p.m. ET on Thursday, July 29, 2010.

Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at www.abaxis.com. A replay of the call is available by visiting www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 442697, through August 3, 2010.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

Contact: Clint Severson Lytham Partners, LLC Joe Dorame, Joe Diaz & Chief Executive Officer Robert Blum Abaxis, Inc. 602-889-9700 510-675-6500

SOURCE Abaxis, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Tobira's Next-Generation Once-Daily CCR5/CCR2 Anta...
S
Women Gather in DC to Speak Out About Prostate Can...